Slide 1: Third Quarter 2016 Earnings Teleconference
Third Quarter 2016 Earnings Teleconference November 1, 2016
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Third Quarter 2016 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Third Quarter 2016 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Q3 2016 was Pfizer's eighth consecutive quarter of operational revenue growth Innovative Health's key brands continue to deliver strong growth ▪ Ibrance, Eliquis, Xeljanz, Lyrica and Chantix We remain confident that the Essential Health business has the potential to transition
Slide 6: Pipeline Update
Pipeline Update Oncology Summary of upcoming milestones in 2016 Ibrance (60 programs; 24 non-breast) Potential EU decision for Ibrance Xtandi (FDA approved TERRAIN data; now Avelumab US filing in Merkel cell working to generate data in earlier PC) carcinoma Immuno-oncology (10 compound
Slide 7: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Third Quarter 2016 Earnings
Slide 8: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Third Quarter 2016 2015 Change Revenues $13,045 $12,087 8% Reported Net Income(1) 1,320 2,130 (38%) Reported Diluted EPS(1) 0.21 0.34 (37%) Adjusted Income(2) 3,726 3,728 — Adjusted Diluted EPS(2) 0.61 0.60 2% Q3 2016
Slide 9: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Third Quarter 2016 2015 FX Impact Revenues $13,045 $12,087 ($224) (2%) Adjusted Cost of Sales(1) 2,957 2,108 (189) (9%) Adjusted SI&A Expenses(1) 3,531 3,276 69
Slide 10: 2016 Financial Guidance
2016 Financial Guidance(1)(2) $52.0 to $53.0 billion Revenues (previously $51.0 to $53.0 billion) 21.5% to 22.0% Adjusted Cost of Sales(3) as a % of Revenues (previously 21.0% to 22.0%) $14.2 to $14.7 billion Adjusted SI&A Expenses(3) (previously $13.7 to $14.7 billion) $7.8 to $8.1 billion Adjusted
Slide 11: Key Takeaways
Key Takeaways Achieved another strong quarter of Pfizer operational revenue growth, primarily driven by: The incremental contribution from a full quarter of the legacy Hospira business, as well as the continuing solid performance of Ibrance, Eliquis, Xeljanz, Lyrica & Chantix Narrowed ranges for c
Slide 12: Q&A Session
Third Quarter 2016 Earnings Teleconference Q&A Session November 1, 2016
Slide 13: Appendix: Segment Financial Highlights
Appendix Segment Financial Highlights November 1, 2016
Slide 14: Pfizer Innovative Health Selected Financial Highlights
Pfizer Innovative Health Selected Financial Highlights ($ Millions, Except Percentages) Third Quarter Q3 2016 revenues increased 10% operationally to $7,332M vs. Q3 2015 % Change 2016 2015 Driven by Ibrance in the U.S., Eliquis globally, as Total Oper. well as Xeljanz, Lyrica and Chantix/Champix
Slide 15: Pfizer Essential Health Selected Financial Highlights
Pfizer Essential Health Selected Financial Highlights ($ Millions, Except Percentages) Q3 2016 revenues increased 10% operationally to Third Quarter $5,712M vs. Q3 2015 Driven by the inclusion of legacy Hospira operations % Change 2016 2015 (HSP) Total Oper. Excluding HSP, revenues declined 5%